Greenwich LifeSciences, Inc.
$24.29
-15%Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -17.0).
Valuation inputs: P/E -17.0, earnings yield N/A, momentum -14.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -10.8%, ROIC +2.9%).
Profitability stack: net margin 0.0%, ROE -10.8%, ROIC +2.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
Medium confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets N/A, momentum -14.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Greenwich LifeSciences, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Greenwich LifeSciences, Inc. Fair Value Envelope
No Revenue Data
GLSI has not reported any revenue values in the available annual periods.
Greenwich LifeSciences, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
GLSI has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
GLSI has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
GLSI has not reported any net profit margin values in the available annual periods.
Greenwich LifeSciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Greenwich LifeSciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Greenwich LifeSciences, Inc. Street Expectations Map
Wall Street analysts project that GLSI stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 50.00, with estimates ranging from a low of 50.00 to a high of 50.00.
The consensus 1-year price target stands at 50.00, with estimates ranging from a low of 50.00 to a high of 50.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Greenwich LifeSciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $489K worth of GLSI shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
16.0K
340.17K
0
0.00
+340K
+$340K
6-9 Months
17.5K
149.16K
0
0.00
+149K
+$149K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Patel Snehal
Director, 10 Percent Owner, Officer: Ceo And Cfo
$489K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $489K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
No Dividend Yield Data
GLSI has not reported any dividend yield values in the available annual periods.
glsi Dividend History
Learning Layer
Related Guides
Build conviction on GLSI by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.